In a murine model of diet‐induced NASH and fibrosis, the triple combination of GLP‐1R, GCGR, and GIPR monoagonists increased bodyweight loss, reduced liver triglycerides, and improved histological NASH disease activity score; weight loss was similar to that obtained with liraglutide alone, but histological NASH disease activity score was significantly improved (p < 0.01).137. Here, GCGR is linked to metabolic dysfunction-associated steatohepatitis.